In the clinical trial of the anti-IL-5 mAb, mepolizumab, there was significant improvement in the nasal polyposis severity, VAS score, endoscopic nasal polyp score, and all individual VAS symptom scores in the mepolizumab compared with placebo groups (40). The gene discussed is IL5; the disease is Nasal polyposis.